Lunginnov s.a.s. develops, produces and commercializes a large variety of products including ENDOCAN biomarkers . The name of "LUNGINNOV" was chosen since Endocan / ESM-1 was originally discovered in activated endothelial cells from the lung by Dr. Lassalle and his team from the Institut Pasteur de Lille (France).
Lunginnov's innovative solutions allow clinicians and researchers to study or diagnose endothelial dysfunction in various pathologies (sepsis, cancer, COPD, etc?)
Lunginnov can offer to you two types of products:
1.Products ? only for research ? purposes (antibodies, recombinant proteins, kits?) to study vascular remodeling (cancer, angiogenesis, inflammation, sepsis, obesity?).
2.CE marked ELISA kits for diagnosis and/or prognosis and/or the follow-up of patients under treatment in domains of sepsis and cancer.
Lunginnov develops also innovative R&D programs to offer better solutions to investigators involved in endothelial dysfunction.